Nautilus Unveils Voyager Instrument, Launches Early Access Program with Cash Runway to 2027
Nautilus unveiled its Voyager proteomics instrument and launched the Iterative Mapping Early Access Program ahead of schedule, targeting pre-orders in late 2026 and installations in early 2027. The company closed Q4 with $156.1M cash, cut 2025 operating expenses 18%, and expects $65–70M cash burn and ~$0.5M services revenue in 2026.
1. Commercialization Progress
Nautilus publicly unveiled its Voyager instrument at a major proteomics conference and launched the Iterative Mapping Early Access Program in January, transitioning to active customer engagement by allowing sample submissions and feedback. The company plans pre-orders in late 2026 and first instrument installations in early 2027 while building initial sales capacity.
2. Collaborations and Assay Pipeline
Partnerships with the Buck Institute and Allen Institute generated novel tau proteoform data, with the first tau assay verified for early access by the end of Q1. A $1.6M Michael J. Fox Foundation–funded project will develop an alpha-synuclein assay for Parkinson’s research, and oncology proteoform assays are slated for early access in H2 2026.
3. Financial Performance
Nautilus reduced full-year 2025 operating expenses by 18% to $66.8M and ended Q4 with $156.1M in cash equivalents and investments. Q4 operating expenses were $15.4M, down 23% year-over-year, reflecting lower R&D and G&A costs following a reduction in force.
4. 2026 Outlook
Management forecasts a 2026 cash burn of $65–$70M, extending runway through 2027, and projects approximately $0.5M in services revenue, with significant instrument-driven revenue ramp beginning in 2027. Operating expenses are expected to rise as platform development and sales capacity expansion accelerate.